The Journal of clinical endocrinology and metabolism, 108(1), 412
Compound class Synthetic cyclic melanocortin peptide Primary therapeutic relevance Central sexual-desire signaling Approved product VYLEESI bremelanotide injection FDA approval date June 21, 2019 Approved population Premenopausal women with acquired, generalized HSDD Not approved for Men, postmenopausal women, ED, or performance enhancement Terminology clarification: PT-141 generally refers to bremelanotide free base or the active peptide, while the approved drug product contains bremelanotide acetate in a specific sterile injectable formulation
Article 9 mins Supply Chain or Distribution Failure: Navigating the New Normal Supply chain failure ranks seventh globally in 2025 and is projected to fall to twelfth place by 2028
Echocardiography analysis of sham and MI rats with and without exposure to cigarette smoke exposure We performed echocardiogram-based morphological and functional assessment of all animals
TIRZEPATIDE Tirzepatide is an advanced weekly GLP-1 and GIP medication that helps support long-term weight management
